Literature DB >> 26202503

Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics.

Chung-Feng Huang1,2,3,4, Ming-Lun Yeh1, Jia-Jung Lee4,5, Mei-Chin Chen6, Chia-Yen Dai1,4,6, Jee-Fu Huang1,4,7, Jer-Ming Chang5,7,8, Hung-Chun Chen5,8, Shang-Jyh Hwang5,8, Wan-Long Chuang1,4, Ming-Lung Yu9,10.   

Abstract

PURPOSE: Hepatitis B virus (HBV) and HCV might cause reciprocal interference. We aimed to elucidate the influence of HCV and interleukin-28B (IL-28B) genetic variants in the HBV DNA and HBsAg levels in uremic HBV carriers.
METHODS: Assessment of HCV and HBV viral loads, HBsAg levels and IL-28B genotype were performed in 229 HBsAg-positive patients from a cohort of 1,681 uremics.
RESULTS: Patients with HCV viremia had significantly lower HBV DNA (2.58 ± 0.80 vs. 3.16 ± 1.48 log IU/mL, p = 0.005) and HBsAg levels (1.33 ± 1.35 vs. 2.23 ± 1.31 log IU/mL, p = 0.002) compared with those without. IL-28B rs8099917 genotype had no impact on HBsAg and HBV DNA levels. In multivariate regression analysis, HCV RNA levels had a more significant negative correlation with HBsAg levels [β -0.905; 95 % confidence interval (CI) -1.477, -0.334; p = 0.002] than with HBV DNA levels (β -0.586; 95 % CI -1.206, 0.034; p = 0.06). The serum HBV DNA and HBsAg levels had a positive correlation (r = 0.43, p < 0.001) among the 215 HBeAg-negative patients. However, the correlation was not observed in patients with HCV viremia (r = 0.23, p = 0.29). Linear regression analysis revealed that age (β -0.286; 95 % CI -0.043, -0.014; p < 0.001) and the HBV DNA level (β 0.373; 95 % CI 0.239, 0.549; p < 0.001) correlated independently with the HBsAg level among HBeAg-negative patients without HCV viremia, but not among those with concomitant HCV viremia.
CONCLUSIONS: HCV viremia suppressed both HBsAg and HBV DNA levels. The HBsAg levels correlated with the HBV DNA levels only in patients without concomitant HCV viremia.

Entities:  

Keywords:  Dual infection; HBV; HBsAg; HCV; Uremia

Year:  2014        PMID: 26202503     DOI: 10.1007/s12072-014-9527-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  37 in total

1.  Lack of impact of hepatitis C virus coinfection in end-stage renal disease patients with hepatitis B virus infection.

Authors:  R S Moutinho; R M Perez; F H L Pace; A S P Ferreira; M Cendoroglo; J O Medina-Pestana; V P Lanzoni; A E B Silva; M L G Ferraz
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

2.  Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.

Authors:  Tin Nguyen; Alexander J V Thompson; Scott Bowden; Catherine Croagh; Sally Bell; Paul V Desmond; Miriam Levy; Stephen A Locarnini
Journal:  J Hepatol       Date:  2010-02-16       Impact factor: 25.083

3.  Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?

Authors:  J-F Huang; W-L Chuang; C-Y Dai; C-K Ho; S-J Hwang; S-C Chen; Z-Y Lin; L-Y Wang; W-Y Chang; M-L Yu
Journal:  J Intern Med       Date:  2006-09       Impact factor: 8.989

4.  Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

Authors:  Jerzy Jaroszewicz; Beatriz Calle Serrano; Karsten Wursthorn; Katja Deterding; Jerome Schlue; Regina Raupach; Robert Flisiak; C-Thomas Bock; Michael P Manns; Heiner Wedemeyer; Markus Cornberg
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

5.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Authors:  Yen-Tsung Huang; Chin-Lan Jen; Hwai-I Yang; Mei-Hsuan Lee; Jun Su; Sheng-Nan Lu; Uchenna H Iloeje; Chien-Jen Chen
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

6.  Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.

Authors:  Chung-Feng Huang; Ming-Lung Yu; Jia-Horng Kao; Tai-Chung Tseng; Ming-Lun Yeh; Jee-Fu Huang; Chia-Yen Dai; Zu-Yau Lin; Shinn-Cherng Chen; Liang-Yen Wang; Suh-Hang Hank Juo; Wan-Long Chuang; Chen-Hua Liu
Journal:  J Clin Virol       Date:  2013-04       Impact factor: 3.168

Review 7.  T cell function in chronic renal failure and dialysis.

Authors:  C J Kelly
Journal:  Blood Purif       Date:  1994       Impact factor: 2.614

8.  Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study.

Authors:  I S Sheen; Y F Liaw; D Y Lin; C M Chu
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

Review 9.  Impact of hemodialysis therapy on hepatitis C virus infection: a deeper insight.

Authors:  F Fabrizi; P Messa; P Martin
Journal:  Int J Artif Organs       Date:  2009-01       Impact factor: 1.595

10.  Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.

Authors:  Ming-Lung Yu; Chen-Hua Liu; Chung-Feng Huang; Tai-Chung Tseng; Jee-Fu Huang; Chia-Yen Dai; Zu-Yau Lin; Shinn-Cherng Chen; Liang-Yen Wang; Suh-Hang Hank Juo; Wan-Long Chuang; Jia-Horng Kao
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more
  4 in total

1.  Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.

Authors:  Chung-Feng Huang; Tyng-Yuan Jang; Po-Liang Lu; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.

Authors:  Po-Yao Hsu; Yu-Ju Wei; Jia-Jung Lee; Sheng-Wen Niu; Jiun-Chi Huang; Cheng-Ting Hsu; Tyng-Yuan Jang; Ming-Lun Yeh; Ching-I Huang; Po-Cheng Liang; Yi-Hung Lin; Ming-Yen Hsieh; Meng-Hsuan Hsieh; Szu-Chia Chen; Chia-Yen Dai; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Jer-Ming Chang; Shang-Jyh Hwang; Wan-Long Chuang; Chung-Feng Huang; Yi-Wen Chiu; Ming-Lung Yu
Journal:  Clin Mol Hepatol       Date:  2020-12-03

3.  Scaling up the in-hospital hepatitis C virus care cascade in Taiwan.

Authors:  Chung-Feng Huang; Pey-Fang Wu; Ming-Lun Yeh; Ching-I Huang; Po-Cheng Liang; Cheng-Ting Hsu; Po-Yao Hsu; Hung-Yin Liu; Ying-Chou Huang; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  Clin Mol Hepatol       Date:  2020-12-03

4.  The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.

Authors:  Jia-Jung Lee; Yu-Ju Wei; Ming-Yen Lin; Sheng-Wen Niu; Po-Yao Hsu; Jiun-Chi Huang; Tyng-Yuan Jang; Ming-Lun Yeh; Ching-I Huang; Po-Cheng Liang; Yi-Hung Lin; Ming-Yen Hsieh; Meng-Hsuan Hsieh; Szu-Chia Chen; Chia-Yen Dai; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Jer-Ming Chang; Shang-Jyh Hwang; Chung-Feng Huang; Yi-Wen Chiu; Wan-Long Chuang; Ming-Lung Yu
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.